Segment Information (Tables)

9 Months Ended

Sep. 30, 2026

Reconciliation of revenue from segments to consolidated

The following table includes additional information about reported segment revenue, significant segment expense and segment measure of profitability:


	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
(In millions)	2026		2025		2026		2025
Total revenue	$	2,804.1	$	2,534.7	$	8,017.9	$	7,611.2
Less cost and expense:
Cost of sales, excluding amortization and impairment of acquired intangible assets:
Product cost of sales	541.6		384.0		1,602.6		1,261.2
Royalty cost of sales	206.8		290.4		583.7		647.5
Research and development:
Research and discovery	54.2		41.0		136.3		131.9
Early stage programs	87.1		59.9		205.4		184.2
Late stage programs	176.0		60.4		398.3		154.4
Marketed products	112.7		107.7		418.7		284.9
Other research and development costs(1)	144.0		167.1		483.9		513.8
Acquired in-process research and development, upfront and milestone expense	283.8		2.1		481.8		249.4
Selling, general and administrative	752.0		594.8		2,069.0		1,751.1
Other segment expense(2)	466.5		360.8		1,241.8		1,091.0
Net (loss) income attributable to Biogen Inc.	$	(20.6)	$	466.5	$	396.4	$	1,341.8

(1) Other research and development costs primarily consist of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as management costs, as well as depreciation, information technology and facility-based expenses and are not allocated to a specific program or stage.

(2) Other segment expense includes: amortization and impairment of acquired intangible assets; collaboration profit sharing/(loss reimbursement); (gain) loss on fair value remeasurement of contingent consideration; restructuring charges; other (income) expense, net; and income tax (benefit) expense